

**sodium oxybate (XYREM)**

**calcium oxybate/ magnesium oxybate/ potassium oxybate/**

**sodium oxybate (XYWAV)**

**Diagnoses Considered for Coverage:**

- Treatment of cataplexy associated with narcolepsy
- Treatment of excessive daytime sleepiness (EDS) associated with narcolepsy
- Idiopathic hypersomnia – Xywav

**Coverage Criteria:**

**1. For cataplexy associated with narcolepsy:**

- Narcolepsy is confirmed by sleep study, **and**
- Patient is currently NOT on any sedative hypnotic agents or other CNS depressants, **and**
- Dose does not exceed FDA label maximum, **and**

**2. For excessive daytime sleepiness associated with narcolepsy:**

- Narcolepsy is confirmed by sleep study, **and**
- Patient is currently NOT on any sedative hypnotic agents or other CNS depressants, **and**
- Inadequate response, intolerable side effect, or contraindication to modafinil (Provigil), **and**
- Dose does not exceed FDA label maximum.

**3. For Xywav request and diagnosis of idiopathic hypersomnia:**

- Sleep study with multiple sleep latency (MSLT) confirms idiopathic hypersomnia, **and**
- Being recommended or prescribed by a sleep specialist, **and**
- Patient is currently not on any sedative hypnotics (i.e., sleeping agents) or CNS depressants (i.e., narcotics, antidepressants, antipsychotics), **and**
- Inadequate response, intolerable side effect, or contraindication with modafinil (Provigil), **and**
- Dose does not exceed FDA label maximum.

**Coverage Duration:** one year

Effective Date: 8/30/2023